Corcept Therapeutics faces investigation amid FDA challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy CORT?
Source: Businesswire
Corcept Therapeutics Inc's stock has plunged 22.75%, hitting a 52-week low, as the company faces serious allegations of securities fraud.
Pomerantz LLP is investigating claims against Corcept, particularly in light of the FDA's Complete Response Letter regarding relacorilant, which requires additional evidence despite the GRACE trial meeting its primary endpoint. This investigation could lead to significant legal repercussions, further undermining investor confidence and contributing to the stock's volatility.
The ongoing legal scrutiny and regulatory challenges may hinder Corcept's ability to recover in the market, as investors remain cautious amid these developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 35.970
Low
50.00
Averages
91.00
High
121.00
Current: 35.970
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Corcept Therapeutics, seeking damages for investors who purchased securities between October 31, 2024, and December 30, 2025, highlighting serious concerns regarding the company's compliance and transparency.
- False Statements Allegations: The complaint alleges that the company made materially false statements regarding the strength of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The lawsuit also claims that Corcept executives misled investors by conveying confidence in relacorilant's regulatory prospects, asserting no obstacles to approval, while failing to disclose known material risks, which could lead to significant investor losses.
- Investor Rights Protection: Investors have until April 21, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
Corcept Faces Lawsuit Over Ignoring FDA Warnings, Stock Plummets 50%
- Lawsuit Allegations: Hagens Berman has filed a securities class action against Corcept Therapeutics, alleging that the company misled investors about its lead product relacorilant's regulatory viability between October 2024 and December 2025, claiming it had 'powerful evidence' while the FDA warned of inadequate clinical data, leading to significant investor losses.
- Ignored FDA Warnings: The lawsuit highlights that Corcept's management was aware of FDA warnings regarding 'significant review issues' prior to filing the NDA, yet they proceeded with assurances to investors that no impediments existed, potentially violating the Securities Exchange Act.
- Stock Price Reaction: Following the lawsuit announcement, Corcept's stock plummeted by 50%, indicating a severe loss of investor confidence and a pessimistic outlook on the company's future prospects, which may lead to further capital outflows.
- Investor Action: Affected investors are urged to contact the law firm by April 21, 2026, to seek lead plaintiff status, demonstrating that legal actions could have profound implications for the company's financial health moving forward.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected shareholders and enhance the lawsuit's impact.
- FDA Approval Risks: The lawsuit claims that Corcept misrepresented the strength of its clinical trial data supporting its New Drug Application, while the FDA had raised concerns about the adequacy of this evidence, potentially leading to significant financial losses for the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Corcept Faces Securities Fraud Class Action
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for making misleading statements between October 31, 2024, and December 30, 2025, with investors having until April 21, 2026, to apply as lead plaintiffs, highlighting significant investor concerns regarding corporate transparency.
- False Statements Allegation: The complaint alleges that the company overstated the strength of clinical trials supporting its New Drug Application (NDA), claiming “powerful support,” while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The company is accused of falsely conveying confidence in the regulatory prospects of relacorilant by asserting smooth communication with the FDA and no anticipated obstacles, despite the FDA's actual concerns regarding clinical evidence, which could impact future approval processes.
- Investor Loss Risks: Due to the aforementioned false statements, investors were not informed of the significant risk that Corcept's relacorilant NDA might not be approved, leading to a misrepresentation of the company's business and prospects, which could result in broader legal and financial repercussions.
See More
Class Action Lawsuit Filed Against Corcept Therapeutics
- Lawsuit Background: Rosen Law Firm has initiated a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding key clinical trials, resulting in shareholder losses.
- Legal Process: Investors wishing to serve as lead plaintiffs must file their motions with the court by April 21, 2026, establishing their representative status in the litigation to protect their interests effectively.
- Compensation Mechanism: Investors joining the class action will incur no upfront costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on affected investors and encouraging broader participation.
- Reputation Damage: The lawsuit claims that Corcept failed to disclose the inadequacy of clinical evidence when submitting its New Drug Application to the FDA, leading to investor losses upon the revelation of the truth, which may have long-term implications for the company's future financing and market trust.
See More
Corcept Therapeutics Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by April 21, 2026, to participate in the securities fraud class action against Corcept Therapeutics (NASDAQ:CORT), which involves stock purchases made between October 31, 2024, and December 30, 2025, indicating a significant loss of investor confidence in the company's future prospects.
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant, resulting in a 50.42% drop in stock price to $34.80 per share, highlighting the direct impact of regulatory risks on the company's market valuation.
- Clinical Development Concerns: The updated CRL revealed that the FDA had significant concerns regarding the adequacy of Corcept's clinical development program to assess relacorilant's effectiveness, suggesting that the company failed to meet regulatory expectations, which could lead to further review issues and increased investor anxiety.
- False Statements Allegations: The class action alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose the FDA's concerns about the effectiveness assessment of relacorilant, leading to a misunderstanding of the company's prospects and reflecting serious deficiencies in corporate governance and transparency.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Corcept Therapeutics, seeking damages for investors who purchased securities between October 31, 2024, and December 30, 2025, highlighting serious concerns regarding the company's compliance and transparency.
- False Statements Allegations: The complaint alleges that the company made materially false statements regarding the strength of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The lawsuit also claims that Corcept executives misled investors by conveying confidence in relacorilant's regulatory prospects, asserting no obstacles to approval, while failing to disclose known material risks, which could lead to significant investor losses.
- Investor Rights Protection: Investors have until April 21, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
Corcept Faces Lawsuit Over Ignoring FDA Warnings, Stock Plummets 50%
- Lawsuit Allegations: Hagens Berman has filed a securities class action against Corcept Therapeutics, alleging that the company misled investors about its lead product relacorilant's regulatory viability between October 2024 and December 2025, claiming it had 'powerful evidence' while the FDA warned of inadequate clinical data, leading to significant investor losses.
- Ignored FDA Warnings: The lawsuit highlights that Corcept's management was aware of FDA warnings regarding 'significant review issues' prior to filing the NDA, yet they proceeded with assurances to investors that no impediments existed, potentially violating the Securities Exchange Act.
- Stock Price Reaction: Following the lawsuit announcement, Corcept's stock plummeted by 50%, indicating a severe loss of investor confidence and a pessimistic outlook on the company's future prospects, which may lead to further capital outflows.
- Investor Action: Affected investors are urged to contact the law firm by April 21, 2026, to seek lead plaintiff status, demonstrating that legal actions could have profound implications for the company's financial health moving forward.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected shareholders and enhance the lawsuit's impact.
- FDA Approval Risks: The lawsuit claims that Corcept misrepresented the strength of its clinical trial data supporting its New Drug Application, while the FDA had raised concerns about the adequacy of this evidence, potentially leading to significant financial losses for the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Corcept Faces Securities Fraud Class Action
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for making misleading statements between October 31, 2024, and December 30, 2025, with investors having until April 21, 2026, to apply as lead plaintiffs, highlighting significant investor concerns regarding corporate transparency.
- False Statements Allegation: The complaint alleges that the company overstated the strength of clinical trials supporting its New Drug Application (NDA), claiming “powerful support,” while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The company is accused of falsely conveying confidence in the regulatory prospects of relacorilant by asserting smooth communication with the FDA and no anticipated obstacles, despite the FDA's actual concerns regarding clinical evidence, which could impact future approval processes.
- Investor Loss Risks: Due to the aforementioned false statements, investors were not informed of the significant risk that Corcept's relacorilant NDA might not be approved, leading to a misrepresentation of the company's business and prospects, which could result in broader legal and financial repercussions.
See More
Class Action Lawsuit Filed Against Corcept Therapeutics
- Lawsuit Background: Rosen Law Firm has initiated a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding key clinical trials, resulting in shareholder losses.
- Legal Process: Investors wishing to serve as lead plaintiffs must file their motions with the court by April 21, 2026, establishing their representative status in the litigation to protect their interests effectively.
- Compensation Mechanism: Investors joining the class action will incur no upfront costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on affected investors and encouraging broader participation.
- Reputation Damage: The lawsuit claims that Corcept failed to disclose the inadequacy of clinical evidence when submitting its New Drug Application to the FDA, leading to investor losses upon the revelation of the truth, which may have long-term implications for the company's future financing and market trust.
See More
Corcept Therapeutics Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by April 21, 2026, to participate in the securities fraud class action against Corcept Therapeutics (NASDAQ:CORT), which involves stock purchases made between October 31, 2024, and December 30, 2025, indicating a significant loss of investor confidence in the company's future prospects.
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant, resulting in a 50.42% drop in stock price to $34.80 per share, highlighting the direct impact of regulatory risks on the company's market valuation.
- Clinical Development Concerns: The updated CRL revealed that the FDA had significant concerns regarding the adequacy of Corcept's clinical development program to assess relacorilant's effectiveness, suggesting that the company failed to meet regulatory expectations, which could lead to further review issues and increased investor anxiety.
- False Statements Allegations: The class action alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose the FDA's concerns about the effectiveness assessment of relacorilant, leading to a misunderstanding of the company's prospects and reflecting serious deficiencies in corporate governance and transparency.
See More
